alopecia areata

Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy
Tofacitinib
by NEXT STEPS IN DERM TEAM on
INTRODUCTION Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib …
Upadacitinib Therapeutic Cheat Sheet
Upadacitinib
by Alexis Carrington, MD on
Upadacitinib (RINVOQ®) is a once daily oral medication that is FDA approved for a variety of conditions including psoriatic arthritis and atopic dermatitis. Jak inhibitors, like upadacitinib, are a class of drugs showing to be effective in treating inflammatory conditions. Upadacitnib is not only being used to treat  rheumatoid arthritis and psoriatic arthritis, but  was recently FDA approved i …
Oral Minoxidil for Hair Loss | The Expert Weighs In
oral minoxidil for hair loss
by Allison Sit on
INSIDER recently posted an article on oral minoxidil for hair loss as a result of media coverage in The New York Times. Which hair loss patients make good candidates for oral minoxidil? How should a dermatologist determine the best dosage for their patients? For expert advice, I reached out to Shilpi Khetarpal, MD, FAAD, director of cosmetic dermatology and lasers at the Cleveland Clinic. …
Patient Buzz Series: “Jello Skin” and Other Trends
by Allison Sit on
“Jello Skin” is a term that dermatology patients – especially TikTok-using patients – may use in their next office visit. A facialist coined the term when describing glowing, bouncy skin with a lot of collagen similar to Jell-O gelatin. Are you up-to-date on the latest developments and trends in dermatology? Peruse this list of articles in the consumer press and learn about everything fro …
JDD Issue Highlights | April 2022
psoriasis
by NEXT STEPS IN DERM TEAM on
The April 2022 issue of the Journal of Drugs in Dermatology (JDD) includes the perfect blend of original articles, case reports, and editorials. With topics ranging from injectable fillers, botulinum toxin in hidradenitis suppurativa, cannabis and cannabinoid product use, to psoriasis, melasma, onychomycosis and everything in between, we share this month’s issue highlights straight from the JDD …